Alex Therapeutics

We’re very pleased to announce positive results from the randomized-controlled trial of our digital therapy for anxiety. Almee, developed in partnership with Vicore Pharma AB, is a mobile app that offers personalized treatment for anxiety based on CBT. The pivotal trial demonstrated significantly reduced levels of anxiety and improved quality of life for people living with pulmonary fibrosis, a chronic and fatal disease. Read the full press release here: https://lnkd.in/dsRU-X8w #alextherapeutics #digitaltherapeutics #dtx

📣 Check out our recent article on the impact anxiety can have on oncology patients: https://lnkd.in/gsxVBbWp Cancer profoundly affects a person's mental health, with many patients experiencing significant emotional and psychological challenges as a result of their diagnosis and treatment. We explored the potential that digitally delivered CBT can have to support this patient population⚕

Great start to the week with HLTH Europe kicking off in Amsterdam today! 🇳🇱 Our CEO and Founder John Drakenberg is attending and excited to meet with fellow digital health enthusiasts and industry peers. Also attending? Get in touch to connect 🤝 🚀

Fall Internships at Alex Therapeutics 🧠 🚀 We are looking for 3 driven individuals eager to apply their previous experiences and education in our rapidly growing Stockholm-based startup with an emphasis on embracing ownership! Join our team in the following roles: Business Development Intern - Full-time Apply here: https://lnkd.in/dYuzSU7C Operations & Finance Intern - Full time Apply here: https://lnkd.in/drciAEmr Marketing Intern - Part-time Apply here: https://lnkd.in/dZ-m_irY All open to: MSc, BSc students and newly graduated Application: Submit your application by May 19. We encourage you to apply as soon as possible as we review applications on a rolling basis. 

Our Head of Backend Engineering, Max Körlinge, attended yesterday's Digital Health Cocktail Hour as a panelist on the topic: AI/ML for Healthcare and Life Sciences, Beyond the Hype 🔬🤖 🖥 What a great get-together for early-stage health innovation startups, investors, and researchers! 🤝 Big thanks to Nordic Science Capital, Amazon Web Services (AWS), AstraZeneca, HealthCap, Karolinska Institutet, and A Working Lab for organizing and hosting the event.

What is Cognitive Behavioral Therapy (CBT) and why is it a commonly used intervention method to treat mental health? 🤔 🧠 Here's a hint: it's a versatile approach that can address common underlying mechanisms across different psychiatric conditions. Read more to learn about the versatility of CBT as a psychotherapy, and the impact that improved mental health can have on the management of chronic illnesses: https://lnkd.in/dfsSxPPh

Most people have never heard of idiopathic pulmonary fibrosis (IPF), though it takes the lives of 40k people each year in the US. Roughly the same number as breast cancer, except no one talks about it. As the name suggests, its causes are a mystery. Frustrating and disheartening to treat, it is, in the words of one physician, “a relentless disease that turns lungs to stone.” Unfortunately, funding for research on IPF is poor. Drugs that can slow its progression have only recently arrived. Still, more than half die within four years of being diagnosed, a survival rate worse than most cancers. Thankfully, my recent survey of the respiratory healthtech market turned up at least two companies working on IPF/PF. The first, IMVARIA, led by Joshua Reicher, M.D. and team, uses AI to analyze lung CT scans to help physicians identify and diagnose IPF much earlier on. That speed is important. On average, it currently takes doctors 2-3 years to diagnose IPF after someone develop symptoms. IMVARIA expects it can reduce this delay, enabling people to start lung-function preserving treatments at an earlier stage. In January, Fibresolve, the company’s lead AI biomarker, received FDA marketing authorization and Breakthrough Device Designation. Shockingly, this is apparently the first-ever clearance of a diagnostic tool of any type in lung fibrosis. The second product is Almee, which offers a 9-week program of digital cognitive behavioral therapy (CBT) specifically focused on the treatment of anxiety symptoms related to pulmonary fibrosis. It’s the result of a collaboration between Alex Therapeutics and Vicore Pharma AB designed to target the significant psychological impact of the disease. No surprise that an unforeseen and deadly diagnosis, which progressively limits physical functioning, can also have a terrible mental burden. Almee was also granted FDA Breakthrough Device Designation, after a recent clinical trial showed its effectiveness in reducing anxiety symptoms and improving health-related quality of life. With more than 250 thousand Americans living with IPF/PF, and its incidence on the rise, I’m grateful that companies are exploring new options to help people get more timely care and life-improving treatment 🙏 cc John Drakenberg Jessica Shull PhD

Come meet us at DMEA - Connecting Digital Health! 📲 🤝 Our CEO John Drakenberg will be speaking at DMEA 2024 in Berlin this week. In tomorrow's session "Digital Therapeutics – a European success story!?", moderated by Ann-Kathrin Weigand, he is joined by Dennis Hermann (Head of Europe at Kaia Health), Franck LE MEUR (CEO at TechToMed), Laura Nelde (Senior Consultant at Flying Health), and Lorenz Winker (Digital Innovation Hub Lead at Novo Nordisk) in discussing the role of partnerships between startups and established healthcare players in promoting DTx, and getting a glimpse of the future of the industry. Looking forward to a fruitful and insightful discussion!

We’re very excited to announce that Almee, developed in partnership with Vicore Pharma AB, has been granted Breakthrough Device Designation from the FDA. The FDA Breakthrough Devices Program designates those medical devices that are evaluated as providing a more effective treatment for life-threatening or irreversibly debilitating diseases. Read the full press release here: https://lnkd.in/dshSA-Vj

Reuters Events Pharma is just around the corner! Our CEO John Drakenberg is on his way to Philly, excited to delve into discussions on digital health partnerships. Will you be there? Feel free to reach out to connect! 🤝